Wirtschaftsnachrichten (Symbolbild).
Montag, 14.08.2023 14:00 von | Aufrufe: 93

Levi & Korsinsky LLP notifies shareholders of BMRN, MAXR, SYF, PGEN of pending class action settlements

Wirtschaftsnachrichten (Symbolbild). pixabay.com

PR Newswire

NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Levi & Korsinsky informs shareholders of BMRN, MAXR, SYF, PGEN that a settlement has been reached in a pending class action lawsuit against each of these companies.  To receive a pro-rata share of the settlement proceeds, members of the class must file a claim form by the designated dates as listed below:

BioMarin Pharmaceuticals Inc. (Nasdaq: BMRN) – A settlement was reached in the class action against BioMarin Pharmaceuticals Inc. in which a settlement fund of $39,000,000 was created for the benefit of class members. The deadline for submitting a claim is October 30, 2023. To find out more, please go to https://zlk.com/settlement/in-re-biomarin-pharmaceuticals-inc-securities-litigation.

Maxar Technologies, Inc. (NYSE: MAXR) - A settlement was reached in the class action against Maxar Technologies Inc. in which a settlement fund of $27,000,000 was created for the benefit of class members. The deadline for submitting a claim is October 20, 2023. To find out more, please go to https://zlk.com/settlement/oregon-laborers-employers-pension-trust-fund-v-maxar-technologies-inc-et-al.

Synchrony Financial (NYSE: SYF) - A settlement was reached in the class action against Synchrony Financial in which a settlement fund of $34,000,000 was created for the benefit of class members. The deadline for submitting a claim is September 07, 2023. To find out more, please go to https://zlk.com/settlement/in-re-synchrony-financial-securities-litigation.

Precigen, Inc. (Nasdaq: PGEN) - A settlement was reached in the class action against Precigen, Inc. in which a settlement fund of $13,000,000 was created for the benefit of class members. The deadline for submitting a claim is November 25, 2023. To find out more, please go to https://zlk.com/settlement/in-re-precigen-securities-litigation.

Levi & Korsinsky did not act as lead counsel or otherwise participate in litigating the above class actions and provides this information to remind class members of the deadlines to submit a claim for a share of any of these settlement funds.


ARIVA.DE Börsen-Geflüster

Kurse

76,56
-0,03%
BioMarin Pharmaceutical Realtime-Chart
Maxar Technologies Chart
1,307
+1,71%
Precigen Chart
42,40
+1,83%
Synchrony Financial Realtime-Chart

Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 4th Floor Suite #427
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/levi--korsinsky-llp-notifies-shareholders-of-bmrn-maxr-syf-pgen-of-pending-class-action-settlements-301900037.html

SOURCE Levi & Korsinsky, LLP

Werbung

Mehr Nachrichten zur BioMarin Pharmaceutical Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Andere Nutzer interessierten sich auch für folgende News